Not FDA-approved1,2,4Evidence: Limited human dataMetabolic and weight

AOD-96041

Also called AOD-9604 acetate1

Key takeaway

AOD-9604 is a lab-made peptide of 16 amino acids: a fragment of human growth hormone (amino acids 177 to 191) with an extra tyrosine added. It is not an FDA-approved drug.1 It was developed as an obesity drug, but FDA reports that the company ended development in 2007 after its largest trial, of 536 people, found no significant weight loss compared with placebo.1 In 2024 FDA staff recommended against adding it to the list of substances pharmacies may use in compounding, and FDA’s advisory committee agreed unanimously.1,2 AOD-9604 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.6

AOD-9604 at a glance

What it isA synthetic 16-amino-acid fragment of human growth hormone (residues 177 to 191 plus an added tyrosine), according to FDA’s 2024 evaluation.1
FDA statusNot FDA-approved. FDA’s 2024 evaluation states that it is not a component of an FDA-approved drug, and FDA lists it among compounding substances that may present significant safety risks.1,4
Human evidenceShort company trials summarized in a single publication and a larger unpublished weight-loss trial that missed its main goal, according to FDA’s evaluation.1
Sport statusFDA’s 2024 evaluation notes that AOD-9604 is on the World Anti-Doping Agency’s list of prohibited substances.1
Evidence strengthLimited human data. The only cited human studies are small, short, uncontrolled, or incompletely reported, such as case series, pilot studies, or trials published only as a conference abstract whose methods and results cannot be checked. How this label is assigned

What is AOD-9604?

AOD-9604 is a synthetic peptide of 16 amino acids, made from the end of human growth hormone (amino acids 177 to 191) with a tyrosine added at the start, according to FDA’s evaluation.1

FDA reports that it was developed in the late 1990s by Metabolic Pharmaceuticals in Australia as an obesity treatment, and that it has since been marketed for many other uses, including weight loss, joint and bone problems and anti-aging.1

How is AOD-9604 thought to work?

FDA’s evaluation describes rodent studies in which AOD-9604 reduced fat formation, increased fat breakdown and lowered body weight, without changing blood sugar or insulin.1

FDA notes reports that it does not bind or activate growth hormone receptors, and states that its molecular targets and mechanism of action remain unknown.1

What do human studies show?

FDA describes a randomized, double-blind, placebo-controlled trial that enrolled 536 adults with obesity for 24 weeks. It found no significant difference in weight loss from placebo at 12 weeks, its main goal, and the company ended development for obesity in February 2007.1

FDA found that in most of the studies it reviewed, AOD-9604 did not show benefit for weight reduction compared with placebo, and that available summaries lacked details on methods and results.1

FDA found no human data for two of the three routes proposed in the nominations, and its adverse-event database search returned no reports. FDA notes that a lack of reports does not show that a substance is safe.1

What the evidence base contains

  • Small, short, or incompletely reported human study The OPTIONS trial: a randomized, double-blind, placebo-controlled weight-loss trial that enrolled 536 adults, known from company filings; FDA found no published report of its methods and results.1
  • Small, short, or incompletely reported human study Six randomized, placebo-controlled company studies summarized in a 2013 safety publication, which FDA found lacked detail on methods and results.1
  • Animal or laboratory research Rodent studies reporting less fat formation and lower body weight, and rat and monkey toxicology studies with possible effects on bone turnover and the liver, described in FDA’s evaluation.1

Evidence-strength label: Limited human data. How this label is assigned

Is AOD-9604 FDA-approved?

No. FDA’s evaluation, dated November 5, 2024, states that neither AOD-9604 nor its acetate salt is a component of an FDA-approved drug, and that there is no United States Pharmacopeia monograph for either.1

FDA staff evaluated both forms for the 503A bulks list, the list of substances pharmacies may use in compounding, for obesity, and concluded that the balance of criteria weighs against adding them.1

A Federal Register notice announced the December 4, 2024 advisory-committee meeting that discussed AOD-9604. According to the minutes, all 12 voting members voted against placing it on the list.2,3

FDA’s compounding safety-risk page, current as of April 22, 2026, lists AOD-9604 among substances whose nominations were withdrawn, citing possible immune reactions, characterization problems and serious adverse events of unclear cause.4

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. AOD-9604 is not among them.5,6

Timeline

  1. Metabolic Pharmaceuticals announces it is ending development of AOD-9604 for obesity, according to FDA’s evaluation.1
  2. A Federal Register notice announces the December 4, 2024 advisory-committee meeting that will discuss AOD-9604.3
  3. FDA staff date their evaluation recommending against adding AOD-9604 to the 503A bulks list.1
  4. FDA’s Pharmacy Compounding Advisory Committee votes 12 to 0 against placing AOD-9604 on the list.2
  5. FDA’s compounding safety-risk page, as last updated, lists AOD-9604 among withdrawn nominations with safety concerns.4

What is still unknown?

How it works: FDA states that its molecular targets and mechanism of action remain unknown.1

Its safety by the routes promoted today, for which FDA found no human data, and the meaning of the bone and liver findings in animal studies.1

FDA’s final decision on the 503A list, which was not part of the sources reviewed through November 15, 2026.1,4

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for AOD-9604: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for AOD-9604 are a bounded selection, not every registration or paper about AOD-9604. For the years before AOD-9604 was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list AOD-9604 as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name AOD-9604 in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

Not FDA-approved; FDA advised against adding it to the compounding list. FDA staff recommended in 2024 against adding AOD-9604 to the 503A compounding list, and FDA lists it among substances that may present significant safety risks. AOD-9604 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of AOD-9604?

Not FDA-approved; FDA advised against adding it to the compounding list. FDA staff recommended in 2024 against adding AOD-9604 to the 503A compounding list, and FDA lists it among substances that may present significant safety risks. AOD-9604 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
1
Source years
2
Drugs@FDA applications
0

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected clinical trial records, regulatory records, and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to AOD-9604?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

2Selected dated records
8Connected citations
2Populated source years2007–2016
1/4Record lanes present

Registered human studies

Trial composition

0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.

PubMed bibliography

Publication composition

2 of 2 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 1Letter 1Research Support, Non-U.S. Gov't 1Review 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
2

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 2 dated records

Research hub

Explore the AOD-9604 evidence record

Open all 2 records →
2Dated records
1Evidence type
2Cited public sources
2Source years

Change ledger

Recently changed for AOD-9604

Open all 2 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

AOD-9604 Metabolic.

PubMed lists PMID 15134286 in Current opinion in investigational drugs (London, England : 2000) as Journal Article, Review, with publication-date metadata of 2004-04 (month precision). PeptideScanner associated the retained record with the identity slug aod-9604. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
November 15, 2007
Evidence lane
Literature metadata
Record added

AOD-9604 does not influence the WADA hGH isoform immunoassay.

PubMed lists PMID 24124033 in Drug testing and analysis as Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-09-30 (day precision). PeptideScanner associated the retained record with the identity slug aod-9604. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
May 11, 2016
Evidence lane
Literature metadata

Official-source collections

Source records for AOD-9604

Open the full research atlas →

Evidence types

Coverage by source year

Selected records span November 15, 2007 to May 11, 2016. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,2,4
  • U.S. Department of Health and Human Services5
Dated updates connected to this profile · 2

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    AOD-9604 does not influence the WADA hGH isoform immunoassay.↗

    PubMed lists PMID 24124033 in Drug testing and analysis as Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-09-30 (day precision). PeptideScanner associated the retained record with the identity slug aod-9604. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    AOD-9604 Metabolic.↗

    PubMed lists PMID 15134286 in Current opinion in investigational drugs (London, England : 2000) as Journal Article, Review, with publication-date metadata of 2004-04 (month precision). PeptideScanner associated the retained record with the identity slug aod-9604. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    FDA evaluation of AOD-9604-related bulk drug substances, November 5, 2024 (briefing document for the December 4, 2024 Pharmacy Compounding Advisory Committee) ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  2. 2
    December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  3. 3
    Federal Register notice 2024-24828 · published 2024-10-25 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List ↗

    Federal Register via GovInfo · Official source · Source checked August 21, 2026

  4. 4
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  5. 5
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  6. 6
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026